Delivery Order SPE2DB22D9207-SPE2DB25FH4WP

Award Date 2/7/25
Potential Completion Date 3/3/25
Potential Value $16K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,405.54 firm fixed-price delivery order is for the supply of KADCYLA 100 MG VIALS, a specialized oncology medication. This award is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. The IDC, valid through...
This federal contract award, with ID SPE2DB22D9239|SPE2DB24FDJ06, was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $20,478.24 firm fixed-price delivery order is for the supply of KADCYLA 100 MG VIALS, with a period of performance through May 13, 2024. DMS Pharmaceutical Group Inc. holds a significant $499,999,999 indefinite delivery contract (IDC) with the DLA under the...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler located in Park Ridge, Illinois. The $15,358.74 contract is for the delivery of Kadcyla 100 mg vials, a specialized oncology medication, by January 14, 2025. This order is placed under DMS Pharmaceutical Group's existing $499,999,999 Indefinite Delivery Contract (IDC) with the DLA, which enables the agency to issue...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $15,915.24, is for the delivery of 100 mg vials of the cancer drug Kadcyla. This delivery order is part of a larger Indefinite Delivery Contract (IDC) held by DMS Pharmaceutical Group with the DLA, valued at $499,999,999 and valid through November 2026. The IDC...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $15,358.74, is for the supply of Kadcyla 100 mg vials, an oncology drug, with a period of performance through May 24, 2024. This order is issued under DMS Pharmaceutical Group's existing indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999,...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $7,679.34 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the supply of KADCYLA 100 MG VIALS and has an ultimate completion date of August 19, 2024. DMS Pharmaceutical Group is a key supplier in the federal pharmaceutical supply chain, providing a wide range of pharmaceutical products and medical supplies to the Department of Defense...
The U.S. Defense Logistics Agency (DLA) awarded a Delivery Order contract valued at $7,679.34 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. This contract is for the delivery of 100 mg vials of the oncology drug Kadcyla. The contract has a completion date of July 5, 2024 and uses a Firm Fixed Price pricing structure. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA...
The U.S. Defense Logistics Agency (DLA) awarded a Firm Fixed Price Delivery Order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $39,982.26 contract, awarded on April 18, 2024, is for the delivery of KADCYLA 160 MG vials by May 9, 2024. This Delivery Order is part of a larger Indefinite Delivery Contract (IDC) with DMS Pharmaceutical Group valued up to $499,999,999, which allows the DLA to issue orders for a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is a delivery order valued at $5,731.36 for the provision of 160 mg vials of the oncology medication Kadcyla. The contract does not have a set-aside designation. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $20,519.60 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of Kadcyla 160 mg vials, a specialized oncology medication, with a period of performance through November 19, 2024. This delivery order is issued under DMS Pharmaceutical Group's $499,999,999 Indefinite Delivery Contract (IDC) with the DLA, which allows the...
  • SPE2DB22D9207
    Indefinite Delivery Contract
  • SPE2DB22D9207-SPE2DB25FH4WP
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $15,915.24 firm fixed-price delivery order contract is for the provision of KADCYLA 100 MG VIALS, a specialized oncology medication. This delivery order is part of a larger $499,999,999 Indefinite Delivery Contract (IDC) that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. The IDC enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide. This contract award is not associated with any set-aside designation.

Generated 5/9/25, 10:23 AM